A phase 1 clinical trial testing this ADC in the metastatic HER-2-overexpressing breast cancer setting (NCT02952729) was recently concluded, and preliminary data showed a good tolerability and antitumor activity [115]. Here, ERBB2 is linked to breast carcinoma.